Justin Stebbing, MD, PhD, from Imperial College Healthcare NHS Trust, London, UK, discusses the physician’s role when it comes to prescribing biosimilars to breast cancer patients and discussing these drugs with them. Prof. Stebbing explains that biosimilars are effective, well-tolerated and much cheaper. However, physicians don’t necessarily know where the pharmacy, the healthcare system or the hospital is obtaining the molecule from.
Recorded at the American Society of Oncology (ASCO) 2017 Annual Meeting held in Chicago, IL